Ambrx Biopharma Inc.
SEC CIK 1836056 · AMAM · last insider filing 2023-09-19
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Dalesandro Margaret | Director | filed 2023 - 2023 |
| O'Connor Daniel J. | Director · President and CEO | filed 2023 - 2023 |
| Maier Paul V | Director | filed 2023 - 2023 |
| Glover Steve C | Director | filed 2023 - 2023 |
| Chang Xiaowei | Director | filed 2023 - 2023 |
| Hermans Kate | Director | filed 2023 - 2023 |
| Loesberg Janet | Director | filed 2023 - 2023 |
| Rupalla Katrin | Director | filed 2023 - 2023 |
| Hu Edward | Director | filed 2023 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Nelson Sonja | Chief Financial Officer | filed 2023 - 2023 |
| Aromando Andrew | Chief Operating Officer | filed 2023 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.